CHICAGO — Adam M. Brufsky, MD, PhD, professor of medicine and co-director of the Comprehensive Breast Cancer Center at the University of Pittsburgh, discusses the results of the MONARCH-2 and PALOMA-1 trials that were presented at the ASCO Annual Meeting.
MONARCH-2 examined the use of abemaciclib (LY2835219, Eli Lilly) with or without fulvestrant (Faslodex, AstraZeneca) and showed that, with the addition of abemaciclib, there is “an embarrassment of riches in the CDK4/6 space,” according to Brufsky. PALOMA-1 demonstrated a trend toward improved OS while also raising questions about whether survival is “the proper endpoint for measuring the efficacy of CDK4/6 inhibitors.”
“I’m not sure we know that yet,” Brufsky said. “I think we have to see.”